NDAORALTABLETPriority Review
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
TAGRISSO (osimertinib) by AstraZeneca is kinase inhibitors [moa]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGRISSO (osimertinib) is an oral tyrosine kinase inhibitor that targets EGFR mutations in non-small cell lung cancer. It is designed to cross the blood-brain barrier and address CNS metastases, offering improved efficacy over first-generation EGFR inhibitors. The drug works by irreversibly binding to mutant EGFR, blocking downstream signaling pathways that drive cancer cell growth.
$1.2BPart D
PeakStable
16.4 years to LOETAGRISSO is a peak-revenue asset with substantial market penetration and stable demand, supporting a large, mature commercial organization.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
Started Jun 2026
90 enrolled
Non-small Cell Lung Cancer
Boosting Osimertinib Blood Brain Barrier Penetration
Started Jun 2026
7 enrolled
Non-Small Cell Lung Cancer
Barriers and Facilitators of Persistence With Adjuvant Osimertinib
Started Jun 2026
100 enrolled
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Started Jun 2026
418 enrolled
Non-small Cell Lung Cancer Stage III
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Started May 2026
100 enrolled
Non-small Cell Lung Cancer
Worked on TAGRISSO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.